Study finds the use of short-acting opioids decreased and the usage of long-acting opioids increased from January 2014 to March 2016.
The increasing opioid utilization is a growing problem. A new study aimed at understanding the utilization patterns of short-acting and long-acting opioids found that the usage of short-acting opioids has decreased over a period of time. Consequently, the usage of long-acting opioids has increased, which accounts for majority of the total opioid costs.
Prime Therapeutics LLC (Prime) undertook the research to describe utilization patterns of opioids that are short acting, long acting, have abuse deterrent formulation (ADF), and have abuse-deterrent properties (ADP). The study was conducted between January 2014 through March 2016. Pharmacy claims of almost 15 million commercially insured members were analyzed for both short- and long-acting opioids. The evaluation also included long-acting opioids with and without abuse-deterrent properties. The study found that the usage of short-acting opioids had decreased and the usage of long-acting opioids had increased.
From 20.5 million opioid claims, the study divided the opioids into 4 categories:
The following trends in each category were observed:
Overall, the increase in long-acting opioid claims slightly brought down the total opioid claims in the study period by 3.9%. These long-acting opioids accounted for 8% of all claims volume and 48.6% of total cost. Whereas, the short-acting opioids represented 92% of claims and 51.4% of cost.
Curbing the Opioid Epidemic Is Imperative
The opioid epidemic is a problem. The FDA has approved 6 ADF products. Six other products are likely to have ADP. However, these 6 products have not been granted FDA approval for label changes. Regardless, all these ADF and ADP products are long-acting opioids. It is critical for insurers to understand opioid utilization trends in order to mandate coverage of abuse deterrent formulations.
“With new laws requiring coverage of abuse-deterrent opioids, future utilization and cost trends in this category could increase,” said Cathy Starner, PharmD, principal health outcomes researcher at Prime. “It is important for insurers to understand both legislation and current utilization patterns to help forecast trend in this drug category.”
Opioids with abuse-deterrent properties are not yet proven to completely eliminate abuse. So besides cost and utilization trends, the 27-month analysis also helps focus on the relationship between ADF opioids and decreased opioid overdoses.
Males With Hemophilia A Report Physical, Mental Burdens of Disease Regardless of Severity
April 25th 2024Self-reported data from adult and pediatric males with hemophilia A show that burden of the disease persists regardless of severity, highlighting a need for improved prophylactic treatment.
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More